Burning Mouth Syndrome (BMS)
Burning mouth syndrome (BMS) is a poorly understood condition in which a person experiences ongoing moderate to severe pain in the tongue and/or mouth. Although the cause of BMS remains unclear, some patterns have become clear to researchers. The pain is generally worst in the late afternoon and early evening, but disappears at night. Most often, more than one part of the mouth is involved. Common areas of burning pain include the tongue, the hard palate (the front part of the roof of the mouth), and the lower lip. Many people recover spontaneously within six or seven years. Dry mouth and altered taste sensations often, but not always, accompany the pain.
BMS is thought to fall in the general category of “neuropathic pain,” meaning that it probably results from altered nerve function, possibly in the nerves carrying taste sensation. Use of drugs in the ACE inhibitor family has been implicated in some cases of burning mouth syndrome, but the reason for this apparent connection remains unclear.
Conventional treatment for BMS consists of drugs used to treat neuropathic pain in general, including anticonvulsants, sedatives in the benzodiazepine family, and tricyclic antidepressants. There is inadequate research at present to determine the precise efficacy of these treatments.
Principal Proposed Treatments for Burning Mouth Syndrome
The supplement lipoic acid has shown promise for the treatment of diabetic neuropathy, another form of neuropathic pain. Lipoic acid has also been studied for burning mouth syndrome with mixed results.5
In a double-blind trial, 60 people with burning mouth syndrome received either lipoic acid (200 mg 3 times daily) or placebo for a period of months.1 Researchers reported that almost all people receiving lipoic acid showed significant improvement, while none of those taking placebo improved, and relative benefits endured at 12-month follow-up. The total lack of benefit seen in the placebo group is difficult to believe, and raises concerns about the study’s reliability. Subsequently, two double-blind trials involving 52 and 39 patients respectively failed to find any benefit for lipoic acid and noted quite a large placebo response.5,6
For more information, including dosage and safety issues, see the full Lipoic Acid article.
Other Proposed Treatments for Burning Mouth Syndrome TOP
The yeast Candida albicans can infect the mouth, causing a condition called “thrush.” Thrush may cause symptoms similar to BMS. Some alternative practitioners believe that excessive candida, or hypersensitivity to it (see Yeast Hypersensitivity), is the cause of many illnesses. For this reason, they recommend using anti-yeast treatments to treat BMS. However, there is no direct evidence to support this approach, and it appears that people with BMS are no more likely to have measurable detectible candida in the mouth than people without it.2
Inconsistent evidence suggests that people with BMS might have deficiencies in various nutrients, such as vitamins B1, B2, and B6, and zinc.3 However, there is no evidence as yet that supplementation with these nutrients will have any effect on BMS symptoms.
References[ + ]
1. Femiano F, Scully C. Burning mouth syndrome (BMS): double blind controlled study of alpha-lipoic acid (thioctic acid) therapy. J Oral Pathol Med. 2002;31:267–269.
2. Ship JA, Grushka M, Lipton JA, et al. Burning mouth syndrome: an update. J Am Dent Assoc. 1995;126:842–853.
3. Ship JA, Grushka M, Lipton JA, et al. Burning mouth syndrome: an update. J Am Dent Assoc. 1995;126:842–853.
4. Sardella A, Lodi G, Demarosi F, et al. Hypericum perforatum extract in burning mouth syndrome: a randomized placebo-controlled study. J Oral Pathol Med. 2008 Mar 6.
5. Carbone M, Pentenero M, Carrozzo M, et al. Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: A double-blind, randomized, placebo-controlled study. Eur J Pain. 2008 Jul 31.
6. Lopez-Jornet P, Camacho-Alonso F, Leon-Espinosa S. Efficacy of alpha lipoic acid in burning mouth syndrome: a randomized, placebo-treatment study. J Oral Rehabil. 2008 Oct 18.
Last reviewed December 2015 by EBSCO CAM Review Board
Last Updated: 12/15/2015
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition.
To send comments or feedback to our Editorial Team regarding the content please email us at firstname.lastname@example.org. Our Health Library Support team will respond to your email request within 2 business days.